Antineoplastic Drugs
Antineoplastic Drugs
Antineoplastic Drugs
WANGO
CANCER
Cancer is a disease characterized by a shift in the
control mechanism that governs cell proliferation and differentiation. Two important groups of genes involved in cancer physiology are oncogenes and Tumuor Suppressor Genes(p53).
CELL-CYCLE KINETICS.
Cell cycle has different phases and it is some of these
phases which are targeted by antineoplastic drugs. There are differences in the duration of cell cycles of different tissues. There are drugs which are cell cycle specific.
(3) Epipodophylotoxins (4) Antibiotics ENZYMES SUBSTITUTED UREA PROTEIN KINASE INHIBITORS HORMONE AND ANTAGONISTS
ALKYLATING AGENTS
Exert cytotoxic effects via transfer of their alkyl groups
to various cellular constituents. Alkylating DNA within the nucleus probably represents the major interaction that lead to cell death. They also react with sulphydryl , amino , hydroxyl, carboxyl and phosphate groups.
form an ethyleneimonium ion that may directly or through formation of a carbonium ion transfer an alkyl group to a cellular constituent. The major site of alkylation within DNA is the N7 position of guanine and this reults in miscoding through abnormal base pairing.
importance to the cytotoxic action of alkylating agents. Though alkylating agents are not cell cycle-specific, cells are most susceptible in late G1 and S phases.
ADVERSE EFFECTS.
Vesicant effects.
Nausea and vomitting. Toxities on Bone marrow, GIT and Gonads. Cyclophosphamide does not have a direct vesicant
ALKYLATING AGENTS.
Cyclophosphamide, Mechlorethemine, melphalan,
NITROSOUREAS
Require biotransformation to derivatives with both
alkylating and carbamoylating activities. They are highly lipid-soluble and can cross bloodbrain barrier. Initial halflife is 6hrs and second half life is 1-2 days. Urinary excretion appears to be the major route of elimanation from the body.
DRUG RESISTANCE
Capability to repair DNA lesions
Decreased permeability of the cell to the alkylating
and protein and produces chromosome breaks. Chemotherapeutic activity is most active in Hodgkins disease. It is also leukomonogenic, teratogenic and mutogenic.
disease and soft tissue sarcoma. Cisplatin and Carboplatin: Kills cells in all stages. Has relatively little effect on the bone marrow. Major antitumuor activity in genitourinary cancers.